Biomaterial-Coated Gold Nanoparticles for Early Bladder Tumor Imaging
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current imaging methods for bladder cancer, such as cystoscopy and CT urography, struggle to detect small tumors accurately, leading to high relapse rates and poor patient outcomes due to their limited sensitivity and specificity, especially for non-muscle invasive bladder carcinoma in situ (CIS).
Innovation Solution
Development of gold nanoparticles coated with thiolated chitosan and a specific integrin-binding peptide, linked via a heterobifunctional crosslinker, for targeted photoacoustic imaging and photothermal therapy, enhancing tumor detection and treatment by exploiting the overexpression of α5β1 integrin in bladder cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If conventional imaging methods (cystoscopy, CT urography) are used for bladder cancer detection, then the imaging process is simple and widely available, but the detection precision and sensitivity are insufficient for early-stage tumors
Solution Approach 1:
The patent introduces photoacoustic contrast agents as intermediaries to enhance tumor detection. These agents accumulate in tumor tissues and convert optical energy to acoustic signals, serving as a mediator between optical imaging (high contrast) and ultrasound imaging (high resolution), thereby achieving both high detection precision and using relatively simple imaging equipment
Solution Approach 2:
The patent employs composite photoacoustic contrast agents combining multiple functional components: tumor-targeting ligands, optical absorbers, and acoustic signal generators. This composite structure enables simultaneous targeting of tumors, optical-to-acoustic energy conversion, and high-resolution imaging, resolving the contradiction between detection precision and system complexity
2Measurement precision
If targeted photoacoustic imaging with ligand-functionalized nanoparticles is used, then the detection precision and specificity are improved, but the manufacturing complexity and cost increase
Solution Approach 1:
The patent segments the nanoparticle structure into distinct functional modules: core material for optical absorption, polymer coating for stability, and ligand moieties for targeting. This modular segmentation allows independent optimization and simplification of each component, making the overall manufacturing process more manageable despite the advanced functionality required
Solution Approach 2:
The patent utilizes parameter changes in the ligand-nanoparticle interaction (affinity constants, binding kinetics) to achieve specific targeting without requiring overly complex nanoparticle structures. By optimizing these biochemical parameters, the system achieves high detection precision through selective tumor binding while maintaining relatively simple nanoparticle fabrication
3Measurement precision
If small tumor lesions are targeted for early detection, then the detection precision is improved, but the signal strength from such small targets becomes weaker and harder to detect
Solution Approach 1:
The patent applies local quality enhancement by concentrating photoacoustic contrast agents specifically at the tumor site through ligand-receptor binding. This localized accumulation creates high signal intensity precisely where needed (at the small tumor lesion) while minimizing background signal, thereby enabling detection of early-stage tumors with weak signals
Solution Approach 2:
The composite nanoparticle structure combines materials with high optical absorption coefficients and efficient photoacoustic conversion. This material composition maximizes the photoacoustic signal intensity generated per unit of absorbed light energy, enhancing the detectability of small tumor lesions that would otherwise produce weak signals
4Measurement precision
If high concentrations of contrast agents are used to enhance signal strength, then the photoacoustic imaging sensitivity is improved, but the risk of photothermal damage to surrounding tissues increases
Solution Approach 1:
The patent uses tumor-targeting ligands as intermediaries to deliver photoacoustic contrast agents selectively to tumor tissues. This targeted delivery achieves high imaging sensitivity at the tumor site while maintaining low overall contrast agent concentration in the body, thereby reducing the risk of photothermal damage to surrounding healthy tissues
Solution Approach 2:
The patent creates local quality differentiation by concentrating contrast agents specifically in tumor regions through active targeting. This results in high signal intensity and imaging sensitivity locally at the tumor, while the surrounding tissues receive minimal contrast agent exposure, thus minimizing photothermal damage risk in non-target areas
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticles provide high-resolution, non-invasive imaging and therapeutic capabilities, enabling early detection and effective treatment of bladder cancer, reducing relapse rates and improving patient outcomes through targeted molecular imaging and photothermal therapy.
Implementation Method 1
PAI is a hybrid imaging modality that combines the high contrast of optical absorption and the high spatial resolution of US generated by chromophores after irradiation by a non-ionizing pulsed laser
Implementation Method 2
metal based nanoparticles... for targeted photoacoustic imaging and photothermal therapy
Data Source
AI summary
Metal based nanoparticles coated with a polymer functionalized with thiol groups and —NH groups are provided. The polymer can be thiolated chitosan, thiolated and aminated alginic acid, thiolated and aminated hyaluronic acid, or a protein such as albumin or gelatin, or a synthetic thiolated and aminated polymer such as α-thio-ω-amino polyethylene glycols. The groups are linked to a ligand of the integrin family receptors via a heterobifunctional crosslinker bearing functional groups able to bind to amino groups such as N-hydroxysuccinimidyl ester group (NHS ester), an isocyanate group (—NCO), an isothiocyanate group (—NCS), a Sulfo-N-hydroxysuccinimidyl ester group (sulfo-NHS ester), or a carboxylic acid group which is connected by activation with carbodiimide coupling agents; and/or a functional group able to bind thiol groups.